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OBJECTIVE—Although interleukin-1 receptor antagonist (IL-
1Ra) treatment is associated with improved -cell function and
glycemic control in patients with type 2 diabetes, its role in the
development of type 2 diabetes remains unclear. We used
repeated measurements to characterize IL-1Ra trajectories in
individuals who developed type 2 diabetes.
RESEARCH DESIGN AND METHODS—This case-cohort
study, nested within the Whitehall II cohort, was based on 335
incident type 2 diabetes cases and 2,475 noncases. We measured
serum IL-1Ra levels at up to three time points per individual and
estimated retrospective trajectories of IL-1Ra before diabetes
diagnosis (case subjects) or end of follow-up (control subjects)
using multilevel analysis. Models were adjusted for age, sex, and
ethnicity.
RESULTS—IL-1Ra levels were already higher in the case than
control subjects 13 years before diabetes diagnosis/end of fol-
low-up (mean [95% CI] 302 [290–314] vs. 244 [238–249] pg/ml). In
control subjects, IL-1Ra levels showed a modest linear increase
throughout the study period. In case subjects, IL-1Ra trajectories
were parallel to those in control subjects until 6 years (95% CI
7.5–4.5) before diagnosis and then rose steeply to 399 (379–420)
pg/ml at the time of diagnosis (P  0.0001 for slope difference).
Adjustment for BMI and waist circumference as time-varying
covariates had little impact on these trajectories.
CONCLUSIONS—We show elevated IL-1Ra levels for 13 years
and an accelerated increase during the last 6 years before type 2
diabetes diagnosis, indicating the presence of an anti-inﬂamma-
tory response that may act to counterbalance the metabolic and
immunologic disturbances that precede type 2 diabetes.
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T
ype 2 diabetes is characterized by insulin resis-
tance and impaired insulin secretion, the latter
being due to a reduction in -cell mass and an
increase in -cell apoptosis (1). Prospective co-
hort studies have shown elevated circulating levels of
acute-phase proteins, cytokines, and chemokines to pre-
dict incident type 2 diabetes (2–6). Interleukin-1 (IL-1)
may be one of the most important immune mediators in
this context because this cytokine triggers various proin-
ﬂammatory events, inhibits -cell function, and promotes
-cell apoptosis (7,8). The deleterious effects of IL-1 can
be inhibited by its naturally occurring antagonist, IL-1
receptor antagonist (IL-1Ra), produced by adipose and
other tissues (9). IL-1Ra competitively binds to the IL-1
receptor without inducing a cellular response (7,10,11).
Animal models and evidence from humans support the
association between IL-1Ra and diabetes. In mice, IL-1Ra
injections have been demonstrated to protect from diabe-
tes induced by high-fat diet (12). A double-blind, parallel-
group trial of 70 patients with type 2 diabetes showed that
the administration of exogenous IL-1Ra (anakinra) im-
proved glycemia, -cell function, and surrogate markers of
systemic inﬂammation (13,14).
A nested case-control study within the Whitehall II study
found that high levels of IL-1Ra were associated with an
increased risk of incident type 2 diabetes. This ﬁnding
suggests that increased IL-1Ra levels may reﬂect a reaction
to counterregulate immunologic and metabolic distur-
bances before the onset of type 2 diabetes—a reaction that
eventually fails (15).
Recent advances in analysis of longitudinal risk factor
trajectories support a multistage model of diabetes devel-
opment. Although the levels of homeostasis model assess-
ment insulin sensitivity (HOMA-2S) and HOMA -cell
function (HOMA-2B) differed between incident cases and
noncases more than a decade before the diagnosis of type
2 diabetes, a substantial divergence in HOMA trajectories,
accompanied by a marked acceleration in the dysregula-
tion of glucose metabolism, became evident during the last
5 years before diagnosis (16). Extending the risk factor
trajectory approach to inﬂammatory biomarkers could
improve our understanding of the pathogenesis of type 2
diabetes by providing insight into inﬂammatory changes
that may be causally related to disease onset (17).
In this report from the Whitehall II study, we examine
the trajectories of serum IL-1Ra in individuals who de-
velop type 2 diabetes and those who remained diabetes-
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circulating IL-1Ra levels would precede diabetes develop-
ment by 5 years before the diagnosis, coinciding with the
previously described changes in insulin sensitivity and
-cell function (16). Changes in IL-1Ra would indicate an
anti-inﬂammatory reaction to counterregulate the proin-
ﬂammatory environment and preserve insulin sensitivity
and -cell function.
RESEARCH DESIGN AND METHODS
Study population. Data are from a nested case-cohort study within the
prospective Whitehall II cohort study of 10,308 British civil servants aged
35–55 years at phase 1 (1985–1988). Details regarding study design, baseline
characteristics, and source population for the case-cohort study have been
described previously (18,19). The study was approved by the University
College London Medical School Committee on the Ethics of Human Research
and conducted according to the Declaration of Helsinki. Written informed
consent was obtained at baseline and renewed at each contact.
Phase 3 (1991–1994), when a 75-g oral glucose tolerance test (OGTT) was
administered for the ﬁrst time, served as baseline for the current study.
Participants were followed through postal questionnaires at 2.5-year intervals
(phase 4: 1995–1996, phase 6: 2001, phase 8: 2006–2007) and through clinical
examinations including an OGTT at phase 5 (1997–1999) and phase 7
(2003–2004). For the case-cohort study, we drew a random sample from the
source population of 6,058 men and 2,758 women who had attended the phase
3 examination. We excluded participants with prevalent type 2 diabetes at
phase 3 (n  42), missing follow-up data on diabetes (n  552), or missing
data for key variables (C-reactive protein [CRP; limited to subjects with CRP
10 mg/l], weight, waist circumference, cholesterol, triglycerides, fasting
glucose, fasting insulin) at baseline (n  2,018) or during follow-up (phases 5
and 7; n  3,049), leading to a case cohort of 2,810 subjects: 335 subjects with
incident type 2 diabetes and 2,475 subjects without incident type 2 diabetes.
Measurements. Diabetes was deﬁned by a fasting glucose of 7.0 mmol/l or
more, or a 2-h postload glucose of 11.1 mmol/l or more (20). Type 2 diabetes
was diagnosed by OGTT (56.4%), self-report (13.1%), or the use of glucose-
lowering medication (30.4%).
We measured blood glucose with the glucose oxidase method on a YSI
model 23A glucose analyzer (phase 3: mean coefﬁcient of variation [CV]
2.9–3.3%) and YSI model 2300 STAT PLUS analyzer (phases 5 and 7: mean CV
1.4–3.1%) (YSI, Yellow Springs, OH) (16). Serum insulin was determined with
an in-house human insulin radioimmunoassay (phase 3: mean CV 7%) and a
DAKO insulin ELISA kit (Dako Cytomation, Ely, U.K.) (phases 5 and 7: mean
CV 4.2–9.3%) (16).
IL-1Ra serum concentrations were measured with the Quantikine ELISA kit
(R&D Systems, Wiesbaden, Germany). Although serum samples were from
three different study phases, blood collection, processing, and storage at
80°C followed the same standard operating procedures. All assays were
performed consecutively in the same laboratory (German Diabetes Center),
and samples from different study phases of the same study participant were
always measured using the same enzyme-linked immunosorbent assay
(ELISA) plate to minimize assay imprecision. Mean intra-assay and interassay
CVs were 2.6 and 7.9%, respectively. The limit of detection was 14 pg/ml. All
samples gave values above the limit of detection.
The following variables were included as time-invariant covariates: sex,
age at the end of follow-up, and ethnicity (0  white, 1  nonwhite). Data for
these were derived from phase 3 and phase 1 questionnaires. Given that
adipose tissue is a major producer of IL-1Ra (9), BMI and waist circumference
(assessed in medical examinations contemporaneously with IL-1Ra measure-
ments) were included as additional covariates and were coded as time-varying
covariates.
Statistical analysis. Statistical analyses were performed using SPSS 14.0
statistical software (SPSS, Chicago, IL). The participants were divided into
case subjects (i.e., individuals who developed type 2 diabetes during the
follow-up) and control subjects (i.e., people who remained diabetes-free).
Initial analyses compared the characteristics of case and control subjects and
tested the differences using t tests and 
2 tests. The unadjusted associations
between IL-1Ra and potential confounding variables were examined and
tested using ANOVA for stratiﬁed measures and Spearman rank correlation
together with unstandardized regression coefﬁcients (95% CIs) of log2(IL-1Ra)
for the continuous variables. For subsequent analyses, year 0 of the observa-
tion period was the year of diabetes diagnosis for case subjects and a
randomly selected time point during follow-up for control subjects to approx-
imate the follow-up time distribution of case subjects. IL-1Ra levels were
traced backwards to participants’ ﬁrst participation in clinical screening (i.e.,
phase 3, which represents the baseline of the current analysis—a maximum of
13 years previously). Multilevel models were ﬁtted to the data to assess
changes in IL-1Ra during these preceding 13 years (21). Of a total of 8,233
serum measurements (964 in case subjects; 7,269 in control subjects), 2,383
measurements after year 0 were excluded and thus the analyses were based
on 755 serum samples in case subjects and 5,095 serum samples in control
subjects. Data were structured so that measurement times (observations)
were nested within subjects, and the standard errors were calculated by
taking into account the nonindependence of the observations, that is, that the
same individuals contributed to more than one observation in the dataset. We
treated observation time as one period (a nonpiecewise approach) for control
subjects and as two distinct periods (a piecewise approach) for case subjects.
In the latter approach, we created two time variables: a continuous variable,
scaled to take the value zero at the start of the second period, and a dummy
variable indicating the period (0  ﬁrst period and 1  second period). We
ﬁrst established the most parsimonious model for each piecewise model and
chose the position of the start of the second period (from 9 to 0) that had the
lowest information criteria for the ﬁnal model. We estimated the likelihood-
based 95% CI for the position of the start of the second period. The selected
model was in close agreement with locally weighted scatter plot smoothers
displaying the association graphically (data not shown). All analyses were
adjusted for age, sex, ethnicity, and study phase. Additional models included
BMI, waist circumference, or insulin as time-varying covariates. To provide
ﬁgures adjusted for baseline characteristics, trajectories were ﬁtted for a
hypothetical population of 72.0% male and 91.2% white at age 62.9 years at the
end of follow-up. Statistical signiﬁcance was inferred at a two-tailed P  0.05.
RESULTS
Study population. The comparison of the study partici-
pants (n  2,810) and excluded subjects (n  6,006) at
baseline showed the study participants to be, on aver-
age, 1.4 years younger than those excluded, but other-
wise revealed only small differences between the groups
(supplementary Table 1, available in an online appendix
at http://diabetes.diabetesjournals.org/cgi/content/full/db09-
1199/DC1). Characteristics of case and control subjects at
baseline (phase 3) are shown in Table 1. Case subjects
(n  335) were older and more overweight than control
subjects (n  2,475). Case subjects also had higher blood
pressure, fasting and 2-h blood glucose, and fasting insulin
and were more likely to be nonwhite. Mean follow-up time
( SD) was 8.8  3.4 years.
Determinants of serum concentrations of IL-1Ra
(univariate analyses). Unadjusted baseline levels of
IL-1Ra were higher in case than control subjects (Table 2).
TABLE 1
Characteristics of incident diabetes case and control subjects at
baseline (phase 3)
Control
subjects
Case
subjects P
n 2,475 335
Age (years) 49.1  5.8 51.0  6.1 0.0001
BMI (kg/m
2) 25.0  3.3 27.1  4.2 0.0001
Waist circumference
(cm) 83.5  10.8 89.2  12.2 0.0001
Systolic blood pressure
(mmHg) 119.5  12.7 123.8  14.3 0.0001
Diastolic blood pressure
(mmHg) 79.3  9.0 82.2  9.6 0.0001
Fasting blood glucose
(mmol/l) 5.2  0.4 5.5  0.5 0.0001
2-h blood glucose
(mmol/l) 5.3  1.4 6.7  1.9 0.0001
Fasting insulin (pmol/l) 36.2  28.8 61.5  46.4 0.0001
Sex, male/female (%) 73.3/26.7 69.9/30.1 0.191
Ethnicity, white/nonwhite
(%) 92.9/7.1 80.6/19.4 0.0001
Data are means  SD or %.
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No differences in IL-1Ra were found among ethnic groups.
In univariate analyses, IL-1Ra was positively correlated
with age, BMI, waist circumference, blood pressure, 2-h
glucose, and fasting insulin (Table 3).
Trajectories of IL-1Ra in case and control subjects.
Multilevel models adjusted for age, sex, and ethnicity
showed that serum IL-1Ra levels were already higher in
case than control subjects 13 years before diagnosis or end
of follow-up. Mean IL-1Ra levels (95% CI) were 302 (290–
314) pg/ml in case subjects and 244 (238–249) pg/ml in
noncase subjects (Fig. 1A).
From years 13 to 6 (95% CI 4.5 to 7.5), the
trajectories of IL-1Ra of case and control subjects were
parallel and increased marginally (1.5 pg/ml per year)
over time. An interaction effect among caseness, time
period, and time indicated that the IL-1Ra trajectories of
case and control subjects began to separate after year 6
(Fig. 1A). From years 6 to 0, IL-1Ra levels in case
subjects increased steeply (13–16 pg/ml per year) and
reached 399 (379–420) pg/ml at the time of diagnosis,
whereas the slope of the IL-1Ra trajectory in the control
subjects remained unaltered (P  0.0001 for the slope
difference during the ﬁnal 6 years; model 1 in Table 4).
Additional adjustment for BMI or waist circumference
as time-varying covariates reduced, but did not remove,
the differences between case and control subjects (Fig. 1B
and C). From years 13 until 6, IL-1Ra levels remained
constant in both case and control subjects after adjust-
ment. From years 6 until 0, IL-1Ra levels in case subjects
increased steeply (11–12 pg/ml per year in BMI-adjusted
and 9–11 in waist-adjusted models), whereas IL-1Ra levels
in control subjects remained unaltered (P  0.001 for the
slope difference during the ﬁnal 6 years; models 2–3 in
Table 4). Adjustment for fasting insulin had hardly any
impact on the difference between case and control sub-
jects from years 13 to 6, but substantially reduced the
increase of IL-1Ra from years 6 to 0 in case subjects (4
pg/ml per year; P  0.05 for the slope difference during the
ﬁnal 6 years; model 4 in Table 4, Fig. 1D).
Estimated trajectories for fasting glucose (supplemen-
tary Fig. 1A), 2-h glucose (supplementary Fig. 1B), HOMA
insulin sensitivity (supplementary Fig. 1C), and HOMA
-cell function (supplementary Fig. 1D) are provided for
direct comparisons with the IL-1Ra trajectories. Apart
from an earlier start of the compensatory increase in -cell
function in the current analysis (year 5 vs. 4), the
shapes of the trajectories are almost identical to those
observed in the larger Whitehall II cohort (16).
DISCUSSION
This case-cohort study of a middle-aged metabolically
healthy population at baseline has three main ﬁndings.
First, circulating concentrations of IL-1Ra were elevated in
cases of incident type 2 diabetes 13 years in advance of
diagnosis compared with individuals who remained diabe-
tes-free. Second, in control subjects, longitudinal changes
could be described by a linear trajectory with only a slight
increase over time, whereas in case subjects, IL-1Ra
increased rapidly starting 6 (95% CI 4.5–7.5) years before
diagnosis. Third, changes in obesity explained the slight
linear increase in control subjects throughout the obser-
vation period and in case subjects up to 6 years before
diabetes diagnosis, but did not account for the steep
increase in the IL-1Ra trajectory among case subjects in
the last 6 years.
Our ﬁndings extend current knowledge on the associa-
tion between inﬂammation and type 2 diabetes develop-
ment, as this is the ﬁrst study to characterize cytokine
trajectories before type 2 diabetes. Our previous report on
IL-1Ra and incident diabetes in a nested case-control study
was limited to a single IL-1Ra measurement at study
baseline (phase 3) (15) and therefore did not provide
information on the time course of IL-1Ra levels preceding
diabetes diagnosis.
Our ﬁndings are also novel from a pathophysiological
perspective because they support the hypothesis that the
pre-diabetic stage is characterized not only by proinﬂam-
matory alterations, but also by the presence of an anti-
inﬂammatory response. Several mechanisms could explain
the upregulation of IL-1Ra before the diagnosis of type 2
diabetes. The steep increase of IL-1Ra in pre-diabetic
individuals occurs within the same time window in which
indicators of insulin sensitivity, -cell function, and glyce-
mia deteriorate (supplementary Fig. 1). This may indicate
that these unfavorable changes in glucose metabolism and
the increase of IL-1Ra production are closely connected.
TABLE 2
IL-1Ra levels in subgroups of the study population at baseline
(phase 3)
Stratiﬁcation variable IL-1Ra (pg/ml) P
Diabetes incidence
Cases 308 (293323)
0.0001 Noncases 248 (244252)
Sex
Male 246 (242251)
0.0001 Female 278 (269287)
Ethnicity
White 255 (251259)
0.78 Nonwhite 253 (238268)
Data are means (95% CI).
TABLE 3
Nonparametric correlations and parametric regression coefﬁcients for the association of anthropometric and metabolic factors with
IL-1Ra (log2) at baseline (phase 3)
Spearman rP  (95% CI) P
Age (years) 0.066 0.0005 0.007 (0.0030.011) 0.0004
BMI (kg/m
2) 0.370 0.0001 0.070 (0.0650.076) 0.0001
Waist circumference (cm) 0.278 0.0001 0.016 (0.0140.018) 0.0001
Systolic blood pressure (mmHg) 0.075 0.0001 0.003 (0.0010.005) 0.0005
Diastolic blood pressure (mmHg) 0.104 0.0001 0.007 (0.0040.009) 0.0001
Fasting blood glucose (mmol/l) 0.035 0.063 0.079 (0.0300.128) 0.0016
2-h blood glucose (mmol/l) 0.210 0.0001 0.086 (0.0710.100) 0.0001
Fasting insulin (mmol/l) 0.283 0.0001 0.005 (0.0050.006) 0.0001
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cytes respond to high glucose concentrations with an
upregulation of IL-1 (22–24), so that increased IL-1Ra
concentrations before type 2 diabetes may represent a
response to glucose-mediated IL-1 upregulation. The
balance between IL-1 and IL-1Ra has been postulated to
be a major determinant of the time course and severity of
inﬂammatory diseases (25,26), and it is conceivable that
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FIG. 1. A–D: Model-predicted IL-1Ra trajectories in nondiabetic and incident diabetic subjects. Year 0 denotes the time of diagnosis for case
subjects and a randomly selected time point during follow-up for control subjects (noncases). All models were adjusted for age, sex, and ethnicity.
Additional adjustment was performed for BMI (B), waist circumference (C), and fasting insulin (D). The table below the panels shows the number
of measurements at each time point for both case and control subjects. Error bars represent 95% CIs around the values estimated by the ﬁxed
effect part of the mixed model presented in Table 4.
TABLE 4
Fixed effects for multilevel models of changes over time in log2(IL-1Ra) serum concentrations before diagnosis of type 2 diabetes or
the end of follow-up
Model 1 Model 2 Model 3 Model 4
Time (per year) 0.004 (0.002)* NS NS 0.005 (0.002)*
Case (incident type 2 diabetes) 0.31 (0.03)† 0.14 (0.03)† 0.13 (0.03)† 0.28 (0.029)†
Case  time NS NS NS NS
Case  time  2nd period 0.052 (0.006)† 0.051 (0.006)† 0.045 (0.006)† 0.013 (0.006)*
BMI (per kg/m
2) — 0.065 (0.002)† — —
Waist circumference (per cm) — — 0.025 (0.001)† —
Data are regression coefﬁcients (SE). Time  continuous variable scaled so that time  0 at 6 years before diagnosis or the end of follow-up.
Case  incident type 2 diabetes case. 2nd period  dummy variable (1 for positive values in the time variable, i.e., later than 6 years before
diagnosis or the end of follow-up; 0 for nonpositive values). Trajectories in 335 case subjects with incident type 2 diabetes were compared
with those in 2,475 control subjects. Log2(IL-1Ra) was the outcome variable of the multilevel longitudinal modeling, and data were adjusted
for age, sex, ethnicity, and study phase. Only models with the lowest information criteria are shown. *P  0.05; †P  0.0001.
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also be relevant in the pathogenesis of type 2 diabetes. We
could not test this hypothesis here because the physiolog-
ical concentrations of IL-1 in individuals without severe
inﬂammatory diseases are so low that they are mostly
undetectable with currently available assays (23,27). How-
ever, it has been suggested that elevation of only IL-1 may
not be sufﬁcient to increase risk of type 2 diabetes; instead,
increased IL-1 in combination with elevated levels of
other proinﬂammatory cytokines may be required (28),
thus limiting the predictive relevance of the IL-1Ra/IL-1
ratio without consideration of other risk factors.
The ﬁnding that the difference in trajectories between
case and control subjects could not be explained by
obesity is important because adipose tissue is a major
producer of IL-1Ra (9,29). We replicated strong correla-
tions of IL-1Ra levels with BMI and waist circumference
(30–33). However, inclusion of BMI or waist circumfer-
ence as time-varying covariates had no major effect on the
shape of IL-1Ra trajectories, suggesting that the upregula-
tion of IL-1Ra cannot directly be attributed to weight gain.
Differences in secretion of leptin, an adipokine strongly
upregulated in obesity that can stimulate IL-1 production
and lead to increased IL-1Ra release, may be one of the
mechanisms involved (34,35).
We did not adjust for glycemia, because our stratifying
variable (incident diabetes caseness) already includes
fasting and/or postload glucose in its deﬁnition, which
means that we have already adjusted for glucose values at
time 0. Because fasting insulin is not included in the
diagnostic criteria, we performed an analysis adjusted for
fasting insulin, which substantially attenuated the slope
difference between case and control subjects preceding
the diagnosis of diabetes. However, a signiﬁcant acceler-
ation of the slope from years 6 to 0 remains among case
subjects, indicating that fasting insulin explains or medi-
ates some, but not all, of the late increase in IL-1Ra. It
should be kept in mind that with our study design, we
cannot directly establish whether this attenuation is due to
confounding, mediation, or shared causation.
Our ﬁndings point to the possibility that shape of
biomarker trajectories is informative in terms of assessing
their predictive value for different time windows. Sequen-
tial measurements of cytokines and other biomarkers and
the characterization of individual trajectories may improve
the estimation of type 2 diabetes risk. Differences in IL-1Ra
levels between case and control subjects varied consider-
ably over the lead time such that IL-1Ra may be more
useful in predicting short-term diabetes risk, whereas
other cytokines may be more strongly associated with
long-term risk of type 2 diabetes. To date, attempts to
improve diabetes risk prediction in the general population
based on biomarker panels measured at a single time point
have produced only marginal improvements compared
with conventional risk models. It remains to be deter-
mined whether it will be possible to improve risk predic-
tion at different pre-diabetic stages in the general
population by considering serial biomarker measurements
over time.
From a therapeutic point of view, it is noteworthy that
recombinant IL-1Ra has been shown to improve metabolic
control in patients with type 2 diabetes (13,14). In this
light, an upregulation of IL-1Ra may be expected to be
protective rather than associated with increased risk. In
our study, it appears that the steep increase of IL-1Ra
levels by approximately one-third was by far not sufﬁcient
to prevent the onset of type 2 diabetes. In the anakinra
trial, an improvement of glycemia and -cell function was
accompanied by supraphysiological IL-1Ra peak levels in
serum that were 	1,000-fold higher in the intervention
group than in the placebo group (13).
Our study has some limitations and strengths that
should be acknowledged. First, the study design does not
enable us to exclude the alternative interpretation that the
increase of IL-1Ra before type 2 diabetes contributes to
the disease risk and represents a causal factor rather than
an anti-inﬂammatory response. However, data from the
anakinra trial (13) as well as preclinical data (12,36) argue
strongly against diabetogenic effects of IL-1Ra. Second, we
did not determine IL-1 levels and therefore cannot know
whether IL-1 increases before type 2 diabetes and
whether such an increase precedes the increase in IL-1Ra.
In addition, we did not have data from all three study
phases for other proinﬂammatory markers, such as CRP
and IL-6, for a comparison of trajectories. We did not
adjust for the available CRP or IL-6 levels at baseline,
because this adjustment has the capacity to inﬂuence only
the intercept of the model, not the shape of the trajecto-
ries, and therefore would not help to answer the question
of temporal sequences. Third, the Whitehall II study is an
occupational cohort and as such is not population based.
Although the cohort was healthy at recruitment, as in a
community-based sample, the cohort overrepresents
white, male, and middle-aged individuals. Fourth, due to
missing data, approximately two-thirds of the source pop-
ulation at phase 3 was excluded from the present analysis.
However, more than 300 incident cases and a total of
almost 6,000 measurement points for the trajectories led
to sufﬁcient statistical power to detect differences be-
tween case and control subjects. In addition, our dropout
analysis (supplementary Table 1) indicates that exclusions
are unlikely to have affected internal validity.
The study has notable strengths. It is based on a
well-phenotyped cohort, and more than half of incident
diabetes cases were diagnosed based on the gold standard
oral glucose tolerance test. We applied a sophisticated
methodology that considered the interrelation among re-
peated measurements from the same individual at different
time points during the follow-up and based our analysis on
a large sample, as noted above.
In conclusion, we characterized cytokine trajectories to
understand the evolution of the association between IL-
1Ra levels in the circulation and type 2 diabetes before the
diagnosis of diabetes. IL-1Ra levels showed an accelerated
increase during the last 6 years preceding diagnosis. We
showed that crude measures of adiposity did not explain
the IL-1Ra trajectory, potentially implicating other factors
in disease susceptibility. These data support the hypothe-
sis that an anti-inﬂammatory response counterbalances
metabolic and immunologic disturbances preceding type 2
diabetes. Moreover, these results suggest that multiple
measurements of inﬂammation-related and other biomar-
kers can markedly improve our understanding of the
pathogenesis of type 2 diabetes. The clear temporal char-
acterization shown by our data may help deﬁne the
optimal clinical use of these biomarkers.
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